Thus, the dual effects of metformin to both enhance TKI cytotoxicity and prevent TKI-induced pulmonary fibrosis makes it an ideal candidate for combinatorial therapy with EGFR-TKIs in NSCLC patients with activated EGFR mutations with the aim of achieving optimal clinical efficacy with minimal side-effect profiles. This evidence concerns the gene EGFR and pulmonary fibrosis.